ORIC presents promising data on Enozertinib at ESMO Asia Congress 2025: 80% ORR in 1L EGFR PACC, 100% intracranial ORR in NSCLC patients with EGFR atypical mutations.

Unusual Whales
2025.12.05 02:46
A recent study revealed promising results for the highly differentiated 1L EGFR PACC treatment, showing a preliminary systemic activity with an 80% Overall Response Rate (ORR) and a 100% intracranial ORR. These results were observed in patients with active brain metastases, indicating a potentially effective treatment option for this group of patients.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer